A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure

ObjectiveTo develop a nomogram model based on the albumin-bilirubin (ALBI) score for predicting the 90-day prognosis of patients with acute-on-chronic liver failure (ACLF) and to evaluate its predictive efficacy.MethodsClinical data of 290 ACLF patients at the Third People’s Hospital of Nantong City...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Ding, Jiandong Shen, Li Zhang, Jianguo Shao, Zhaolian Bian, Hong Xue
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1406275/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841558661960302592
author Wei Ding
Wei Ding
Jiandong Shen
Li Zhang
Li Zhang
Jianguo Shao
Zhaolian Bian
Hong Xue
author_facet Wei Ding
Wei Ding
Jiandong Shen
Li Zhang
Li Zhang
Jianguo Shao
Zhaolian Bian
Hong Xue
author_sort Wei Ding
collection DOAJ
description ObjectiveTo develop a nomogram model based on the albumin-bilirubin (ALBI) score for predicting the 90-day prognosis of patients with acute-on-chronic liver failure (ACLF) and to evaluate its predictive efficacy.MethodsClinical data of 290 ACLF patients at the Third People’s Hospital of Nantong City, collected from December 2020 to December 2023, were analyzed. The data were divided into a training set (n = 200) and a validation set (n = 90), with August 2022 as the cut-off date. Patients in the training set were categorized into an improvement group (n = 133) and a mortality group (n = 67) based on their 90-day outcomes. The predictive power of baseline parameters was assessed using univariate and multivariate logistic regression to construct model. Model performance was assessed using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA) and the Hosmer-Lemeshow test.ResultsCreatinine (CR) [odds ratio (OR) = 1.013, 95% confidence interval (CI): 1.004–1.022], ALBI (OR = 10.831, 95% CI: 4.009–33.247), Gender (OR = 1.931, 95% CI: 0.973–3.870) and ascites (OR = 3.032, 95% CI: 1.249–8.178) were identified as independent prognostic factors. The prognostic model formula was derived as prognostic index (PI) = –0.591 + 0.658 × Gender + 1.109 × ascites + 0.012 × CR + 2.382 × ALBI. The area under the curve (AUC) was 0.804 (95% CI: 0.741–0.866), with a specificity of 85.0% and a sensitivity of 65.7% at a cut-off of 0.425. The AUC of the validation set was 0.811 (95% CI: 0.697–0.926). The Hosmer-Lemeshow test indicated a good model fit with a p-value of 0.287 for the training set and 0.423 for the validation set. Calibration curves demonstrated the accuracy of the model, and DCA results suggested that the model was clinically useful when the threshold was below 0.6.ConclusionThe nomogram model incorporating ALBI with CR, Gender and ascites can predict the 90-day prognosis of ACLF patients, potentially helping to optimize treatment strategies and improve patient outcomes.
format Article
id doaj-art-f64f7105d8e44fb4ac9f796672a8a578
institution Kabale University
issn 2296-858X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-f64f7105d8e44fb4ac9f796672a8a5782025-01-06T06:59:42ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14062751406275A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failureWei Ding0Wei Ding1Jiandong Shen2Li Zhang3Li Zhang4Jianguo Shao5Zhaolian Bian6Hong Xue7Medical School of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaMedical School of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaNantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, Jiangsu, ChinaObjectiveTo develop a nomogram model based on the albumin-bilirubin (ALBI) score for predicting the 90-day prognosis of patients with acute-on-chronic liver failure (ACLF) and to evaluate its predictive efficacy.MethodsClinical data of 290 ACLF patients at the Third People’s Hospital of Nantong City, collected from December 2020 to December 2023, were analyzed. The data were divided into a training set (n = 200) and a validation set (n = 90), with August 2022 as the cut-off date. Patients in the training set were categorized into an improvement group (n = 133) and a mortality group (n = 67) based on their 90-day outcomes. The predictive power of baseline parameters was assessed using univariate and multivariate logistic regression to construct model. Model performance was assessed using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA) and the Hosmer-Lemeshow test.ResultsCreatinine (CR) [odds ratio (OR) = 1.013, 95% confidence interval (CI): 1.004–1.022], ALBI (OR = 10.831, 95% CI: 4.009–33.247), Gender (OR = 1.931, 95% CI: 0.973–3.870) and ascites (OR = 3.032, 95% CI: 1.249–8.178) were identified as independent prognostic factors. The prognostic model formula was derived as prognostic index (PI) = –0.591 + 0.658 × Gender + 1.109 × ascites + 0.012 × CR + 2.382 × ALBI. The area under the curve (AUC) was 0.804 (95% CI: 0.741–0.866), with a specificity of 85.0% and a sensitivity of 65.7% at a cut-off of 0.425. The AUC of the validation set was 0.811 (95% CI: 0.697–0.926). The Hosmer-Lemeshow test indicated a good model fit with a p-value of 0.287 for the training set and 0.423 for the validation set. Calibration curves demonstrated the accuracy of the model, and DCA results suggested that the model was clinically useful when the threshold was below 0.6.ConclusionThe nomogram model incorporating ALBI with CR, Gender and ascites can predict the 90-day prognosis of ACLF patients, potentially helping to optimize treatment strategies and improve patient outcomes.https://www.frontiersin.org/articles/10.3389/fmed.2024.1406275/fullacute-on-chronic liver failureprognosisnomogramrisk factorascites
spellingShingle Wei Ding
Wei Ding
Jiandong Shen
Li Zhang
Li Zhang
Jianguo Shao
Zhaolian Bian
Hong Xue
A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
Frontiers in Medicine
acute-on-chronic liver failure
prognosis
nomogram
risk factor
ascites
title A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
title_full A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
title_fullStr A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
title_full_unstemmed A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
title_short A nomogram model based on albumin-bilirubin score for predicting 90-day prognosis in patients with acute-on-chronic liver failure
title_sort nomogram model based on albumin bilirubin score for predicting 90 day prognosis in patients with acute on chronic liver failure
topic acute-on-chronic liver failure
prognosis
nomogram
risk factor
ascites
url https://www.frontiersin.org/articles/10.3389/fmed.2024.1406275/full
work_keys_str_mv AT weiding anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT weiding anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT jiandongshen anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT lizhang anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT lizhang anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT jianguoshao anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT zhaolianbian anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT hongxue anomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT weiding nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT weiding nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT jiandongshen nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT lizhang nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT lizhang nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT jianguoshao nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT zhaolianbian nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure
AT hongxue nomogrammodelbasedonalbuminbilirubinscoreforpredicting90dayprognosisinpatientswithacuteonchronicliverfailure